16 completed, 16 unknown, 13 recruiting, 6 terminated. 31 Phase 2, 12 Phase 1, 11 Not applicable, 6 Phase 3, 1 Early Phase 1.
Follow EGFR Gene Mutation: new trials by email Literature Review of EGFR Gene Mutation trials Research Report on EGFR Gene Mutation
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| In Vitro NSCLC EGFR-Mutant Models for Drug Sensitivity Testing Carcinoma, Non-Small-Cell Lung, EGFR Gene Mutation | Not yet recruiting | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 30 | 2026-09-01 | 2026-07-13 | |
| An Open-Label, Single-Arm, Dose-Escalation Phase I Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of EDB-102 in Patients With EGFR L858R-Mutant, Third-Generation TKI-Resistant Advanced Non-Small Cell Lung Cancer With Liver Metastases EDB-102 - Non-Small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer | Phase 1 | Not yet recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 15 | 2026-02-10 | 2026-03-10 |
| A Phase II Study of Sacituzumab Tirumotecan in Combination With Furmonertinib in Patients With Non-squamous Non-Small Cell Lung Cancer Who Have Progressed After EGFR-TKI and Platinum-Based Chemotherapy sacituzumab tirumotecan - NSCLC Stage IV, EGFR Gene Mutation | Phase 2 | Recruiting | Tianjin Medical University Cancer Institute and Hospital | 25 | 2026-02-01 | 2026-04-23 |
| EQUAL: EGFR ctDNA QUantative Assessment for Lung Cancer Screening in Asian and Latinx Populations Circulating Tumor DNA (ctDNA) Assay - Lung Cancer, EGFR Gene Mutation | Not applicable | Recruiting | Dana-Farber Cancer Institute | 1000 | 2025-04-01 | 2026-07-15 |
| Whole Body HER3 Quantification With Radiolabelled Patritumab Deruxtecan (HER3-DXd) PET/CT 89Zr-Patritumab deruxtecan - Non-Small Cell Lung Carcinoma, Advanced Non-Small Cell Squamous Lung Cancer | Phase 2 | Recruiting | The Netherlands Cancer Institute | 16 | 2025-03-03 | 2026-08-10 |
| Evaluating High-dose Furmonertinib with Bevacizumab and Pemetrexed for EGFRm NSCLC with Leptomeningeal Metastasis furmonertinib - Non-small Cell Lung Cancer, Leptomeningeal Metastasis | Not applicable | Recruiting | Henan Cancer Hospital | 60 | 2024-12-20 | 2025-03-06 |
| Osimertinib and Etoposide as First-Line Treatment in Osimertinib-Resistant Advanced EGFR-Mutant NSCLC Osimertinib - Non Small Cell Lung Cancer, EGFR Gene Mutation | Phase 2 | Not yet recruiting | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | 93 | 2024-06-01 | 2024-05-30 |
| Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13Ralpha2 CAR (E-SYNC) T Cells E-SYNC T Cells, Cyclophosphamide (non-investigational), Fludarabine (non-investigational) - EGFR Gene Mutation, Glioblastoma | Phase 1 | Recruiting | Hideho Okada, MD, PhD | 20 | 2024-04-30 | 2026-08-13 |
| Adjuvant Target Therapy Guided by ctDNA-MRD in Patients With EGFR-mutant II-IIIA Non-small Cell Lung Cancer (ECTOP-1022) Osimertinib, No adjuvant therapy - Lung Cancer, EGFR Gene Mutation | Phase 3 | Not yet recruiting | Fudan University | 226 | 2024-04-01 | 2024-03-21 |
| Neoadjuvant Almonertinib Followed by Chemo-immunotherapy in II-IIIB EGFR-mutant NSCLC almonertinib, Carboplatin, Nab paclitaxel - Non Small Cell Lung Cancer, EGFR Gene Mutation | Phase 2 | Active not recruiting | Guangdong Provincial People's Hospital | 32 | 2024-04-01 | 2026-04-29 |
| Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients Nintedanib, gefitinib, erlotinib, afatinib, osimertinib - Non-small Cell Lung Cancer, EGFR Gene Mutation | Phase 1 / Phase 2 | Recruiting | China Medical University Hospital | 20 | 2024-02-23 | 2025-01-23 |
| Applying Mobile Healthcare Education to Improve Cutaneous Self-care Capability Mobile healthcare education game, Mobile healthcare education application - EGFR Gene Mutation, Drug-Related Side Effects and Adverse Reactions | Not applicable | Unknown | National Taiwan University Hospital | 110 | 2024-01-26 | 2024-03-04 |
| The Efficacy of Double-dose Furmonertinib in the Treatment of Patients With Slow Osimertinib-resistant NSCLC Furmonertinib - Non Small Cell Lung Cancer, EGFR Gene Mutation | Unknown | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | 30 | 2023-11-01 | 2023-11-07 | |
| Osimertinib Combined With Aspirin Neoadjuvant Therapy for Resectable EGFR Mutated NSCLC Patients. Osimertinib, Aspirin - Non Small Cell Lung Cancer, EGFR Gene Mutation | Phase 2 | Unknown | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | 44 | 2023-09-15 | 2023-09-21 |
| Nitroglycerin Plus Radiotherapy Versus Conventional Radiotherapy in Patients With Lung Cancer. Nitroglycerin - Non-small Cell Lung Cancer, Brain Metastases | Not applicable | Recruiting | Instituto Nacional de Cancerologia de Mexico | 74 | 2023-02-23 | 2026-04-09 |
| A Pilot Study to Understand the Impact of Therapy With Tumour Treating Fields (TTFields) in NSCLC concomitant TTFields treatment device to standard of care EGFR positive NSCLC treatment, concomitant TTFields treatment device to standard of care anti PD-1 NSCLC treatment - Non Small Cell Lung Cancer, EGFR Gene Mutation | Not applicable | Not yet recruiting | Nir Peled | 50 | 2023-01-20 | 2023-01-26 |
| Real-Time Monitoring of Symptoms in Lung Cancer Patients Receiving Oral Targeted Therapies Sensus Smartwatch Application, RX Cap, Fitbit Sense - Lung Cancer, EGFR Gene Mutation | Not applicable | Active not recruiting | University of Virginia | 30 | 2022-08-25 | 2025-11-25 |
| Osimertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR Mutant NSCLC (STEREO) Osimertinib, Stereotactic Body Radiation Therapy (SBRT) - NSCLC Stage IV, EGFR Gene Mutation | Phase 2 | Terminated | ETOP IBCSG Partners Foundation | 6 | 2022-08-04 | 2024-06-28 |
| Tislelizumab +Bevacizumab+pc for Untreated EGFR+ and High PD-L1 Non-squamous NSCLC Tislelizumab Combined With Bevacizumab and Platinum Plus Pemetrexed - Non-squamous Non-small Cell Lung Cancer, EGFR Gene Mutation | Phase 2 | Unknown | Sichuan Cancer Hospital and Research Institute | 20 | 2022-06-01 | 2022-05-27 |
| Feasibility of Intratumoral Washing Fluid for Detecting EGFR Mutations in Lung Cancer Ultarthin bronchoscopy with intratumoral washing - Non Small Cell Lung Cancer, EGFR Gene Mutation | Not applicable | Completed | Pusan National University Hospital | 41 | 2022-04-01 | 2025-08-20 |
Showing 20 of 61. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (40) · Lung Neoplasms (15) · Brain Neoplasms (6) · Neoplasms (4) · Bronchial Neoplasms (3) · Carcinoma, Bronchogenic (3) · Glioblastoma (3) · Lung Diseases (3) · Respiratory Tract Diseases (3) · Respiratory Tract Neoplasms (3) · Thoracic Neoplasms (3) · Adenocarcinoma (2) · Adenocarcinoma of Lung (2) · Carcinoma (2) · Neoplasm Metastasis (2)
Neoplasms (50) · Neoplasms by Site (48) · Respiratory Tract Neoplasms (47) · Thoracic Neoplasms (47) · Lung Diseases (45) · Respiratory Tract Diseases (45) · Bronchial Neoplasms (37) · Carcinoma, Bronchogenic (37) · Lung Neoplasms (35) · Neoplasms, Glandular and Epithelial (8) · Central Nervous System Neoplasms (7) · Nervous System Diseases (7) · Nervous System Neoplasms (7) · Brain Diseases (6) · Central Nervous System Diseases (6)
osimertinib (14) · Pemetrexed (11) · Carboplatin (8) · Gefitinib (8) · Erlotinib Hydrochloride (7) · Afatinib (5) · Bevacizumab (5) · aflutinib (5) · Drug Therapy (3) · aumolertinib (3) · Cisplatin (2) · Gemcitabine (2) · Nivolumab (2) · anlotinib (2) · atezolizumab (2)
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University (3) · Shanghai Pulmonary Hospital, Shanghai, China (3) · Betta Pharmaceuticals Co., Ltd. (2) · Blueprint Medicines Corporation (2) · Fudan University (2) · Fujian Cancer Hospital (2) · Hunan Province Tumor Hospital (2) · Instituto Nacional de Cancerologia de Mexico (2) · M.D. Anderson Cancer Center (2) · Shanghai Chest Hospital (2) · Alpha Biopharma (Jiangsu) Co., Ltd. (1) · Apollomics Inc. (1) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · Centre Francois Baclesse (1) · China Medical University Hospital (1)
China (20) · United States (16) · South Korea (6) · Taiwan (5) · Singapore (4) · Spain (4) · France (3) · Netherlands (3) · Canada (2) · Israel (2) · Italy (2) · Mexico (2) · Russia (2) · United Kingdom (2) · Australia (1)
Anne S Tsao (1) · Caicun Zhou, MD, PHD (1) · Chun Huang (1) · Collin Blakely, MD, PhD (1) · Conghua Xie (1) · Emlio Bria, Prof (1) · Erin Schenk (1) · Giuseppe Giaccone, MD PhD (1) · Grace Dy (1) · Helen Yu, MD (1) · Ioannis Mountzios, MD (1) · Jennifer Clarke, MD, MPH (1) · Jianying Zhou (1) · Jie Wang, M.D. (1) · Joop de Langen, MD (1)
PMID 10999768, PMID 18577994, PMID 19692680, PMID 19692684, PMID 20022809, PMID 20966921, PMID 22736441, PMID 23594426, PMID 23782814, PMID 24312144, PMID 25829397, PMID 25907450, PMID 28212993, PMID 28958502, PMID 30017884, PMID 30207593, PMID 30670498, PMID 30783814, PMID 31411950, PMID 31439584, PMID 31486833, PMID 31587882, PMID 31751012, PMID 34168480, PMID 34512058, PMID 34568058, PMID 34958928, PMID 35724798, PMID 35962934, PMID 36801605, PMID 37244266, PMID 37314501, PMID 37537219, PMID 38830303, PMID 39378386, PMID 39379931, PMID 39389055, PMID 42574006
P30CA014089 (1), U19CA264338 (1)